• leon-nanodrugs Congratulates its Partner MJR Pharmjet on Receiving Prestigious CPhI Award 2017 for Highly Innovative MicroJet Reactor Technology

    Nov 20, 2017 | 09:00 am

    leon-nanodrugs GmbH (http://leon-nanodrugs.com/) in drug development received one of this year’s awards for the highly innovative MicroJet Reactor Technology (http://leon-nanodrugs.com/services/mjr-technology/). leon-nanodrugs is the owner of the MicroJet Reactor Technology for the creation of pharmaceutical nanoparticles and drug delivery systems enabling specific formulations of pharmaceuticals. MJR PharmJet holds a comprehensive patent family covering the technology and

  • CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research

    Nov 17, 2017 | 16:53 pm

    SANTA CLARA, Calif., Nov.17, 2017(GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific[…]

  • Successful First-in-Human Testing of Implandata’s Next Generation EYEMATE™ Micro-Sensor for Improved Monitoring of Glaucoma Patients

    Nov 17, 2017 | 14:30 pm

    Implandata Ophthalmic Products GmbH (http://www.implandata.com/) (Implandata) is a privately held, ISO 13485 certified medical device company founded in 2010 in Hannover/Germany. Implandata’s EYEMATE™ (http://implandata.com/en/was-wir-machen/eyemate/) system for continuous monitoring of intraocular pressure (IOP) and improved disease care at glaucoma patients is providing vastly improved quality and quantity of information on patient’s IOP, which is key for personalized glaucoma care and therapy[…]

  • Sentia Medical Sciences Inc. Announces the Launch of a New Initiative in Stress-related Disorders Targeting Gastrointestinal and Endocrine Diseases

    Nov 17, 2017 | 08:01 am

    SAN DIEGO, Nov.17, 2017(GLOBE NEWSWIRE) -- Sentia announced today that it will bring to fruition several decades of academic research by developing a new generation of first in class drug candidates called astressins. Astressins are peptide antagonists that block the action of corticotropin releasing factor (CRF) and urocortins, the main mediators of the body’s response to stress. CRF and urocortins[…]

  • Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran

    Nov 16, 2017 | 18:40 pm

    VANCOUVER, B.C. and WARMINSTER, Pa., Nov.16, 2017(GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic being developed[…]

  • Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer

    Nov 16, 2017 | 14:25 pm

    Newark, NJ, Nov.16, 2017(GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, announced today, the initiation of a Phase I clinical trial of CPI-613 in combination with chemotherapeutic agents, gemcitabine and nab-paclitaxel, for patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in collaboration with Atlantic[…]

  • BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference

    Nov 16, 2017 | 11:00 am

    RESEARCH TRIANGLE PARK, N.C., Nov.16, 2017(GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 29th Annual Piper Jaffray Healthcare Conference in New York on November 28, 2017 at 3:00 p.m. Eastern Time.Links to a live audio webcast and replay[…]

  • MacroGenics Names Dr. Jay Siegel to its Board of Directors

    Nov 15, 2017 | 21:30 pm

    ROCKVILLE, MD, Nov.15, 2017(GLOBE NEWSWIRE) --MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the appointment of Jay Siegel, M.D., former Chief Biotechnology Officer and Head of Scientific Strategy and Policy at Johnson & Johnson, to its Board[…]

  • Adverum Biotechnologies to Present at Upcoming Conferences

    Nov 15, 2017 | 21:01 pm

    MENLO PARK, Calif., Nov.15, 2017(GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that company executives will present at upcoming conferences in November. Event: The 29th Annual Piper Jaffray Healthcare ConferenceDate: November 28, 2017Time: 12:10 – 12:30 p.m. ETLocation: New York, NYPresentation: Amber Salzman, Ph.D., president and chief executive officer  […]

  • Progressive Care Reports Stellar Third Quarter Results

    Nov 15, 2017 | 13:30 pm

    MIAMI, Nov.15, 2017(GLOBE NEWSWIRE) -- Progressive Care Inc. (OTC PINK:RXMD), through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long term care facilities, administration and practice management, utilization management, quality[…]

  • Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update

    Nov 14, 2017 | 22:40 pm

    Preliminary Data from PTI-428 + Orkambi 28 Day Clinical Study on Track for Q4 2017 Initial Data from PTI-801 + Orkambi 14 Day Clinical Trial Anticipated in Q4 2017 Initial Data from PTI-808 SAD and MAD HV 7 day Study Anticipated in Q4 2017 Initial Data from PTI-808 + PTI-801 + PTI-428 coadministration HV 7 day Study Anticipated in Q4 2017 Dual Combination CF[…]

  • Aptose Reports Results for the Third Quarter EndedSeptember 30, 2017

    Nov 14, 2017 | 21:00 pm

    SAN DIEGO and TORONTO, Nov.14, 2017(GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months ended September 30, 2017 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars. The net loss for[…]

  • NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer

    Nov 14, 2017 | 14:00 pm

    AMES, Iowa, Nov.14, 2017(GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Eugene P. Kennedy, M.D., FACS, to the role of Chief Medical Officer. He will be responsible for leading all clinical development, medical affairs and related functions. Dr. Kennedy’s previous role at NewLink Genetics was Vice President of Clinical and Medical Affairs.“Gene’s considerable experience in clinical[…]

  • Former General Mills Executive Joins Canadian Startup as Advisor

    Nov 14, 2017 | 13:00 pm

    PETERBOROUGH, Ontario, Nov.14, 2017(GLOBE NEWSWIRE) -- Noblegen Inc. (“Noblegen”) — announces the appointment of distinguished industry veteran, Jim Kirkwood, as an official advisor to the Corporation.Kirkwood is a valuable addition to the company’s advisory team. He will support the commercialization of Noblegen’s nutritious ingredients, as well as new product innovation.In welcoming the new advisor, CEO Adam Noble said, “Jim is[…]

  • Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights

    Nov 14, 2017 | 12:00 pm

    -Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO- -Completion of Initial Public Offering Raising Net Proceeds of $129 million--Announced Plans to Initiate Two Pivotal Trials of DCC-2618 in 4th and 2nd Line GIST in 2018-WALTHAM, Mass., Nov.14, 2017(GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug[…]

  • CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

    Nov 14, 2017 | 00:23 am

     Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian CancerGEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018 Following a Phase IB Trial Demonstrating 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated LAWRENCEVILLE, N.J., Nov.13, 2017(GLOBE NEWSWIRE) --In[…]

  • Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)

    Nov 13, 2017 | 22:22 pm

    VANCOUVER, British Columbia and WARMINSTER, Pa., Nov.13, 2017(GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced the grant of an accelerated assessment from the European Medicines Agency (EMA) for patisiran, an investigational RNAi therapeutic being developed for patients with[…]

  • Vetter Expands its Footprint in Asia Pacific Region

    Nov 9, 2017 | 14:40 pm

    Vetter (https://www.vetter-pharma.com/en/home-en), one of the global leaders in prefilled drug-delivery systems (https://www.vetter-pharma.com/en/services), today announced the official opening of a new branch office in South Korea. The new office in Songdo (https://www.vetter-pharma.com/en/company/sites-directions) is located within the biologics cluster which is often referred to as a

  • RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease

    Nov 9, 2017 | 13:15 pm

    Top-line results are expected to be announced in mid-2018The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to severely active Crohn’s diseaseWorldwide sales of Crohn’s disease therapies exceeded $7.6 billion in 2016A pivotal Phase III study with[…]

  • apceth Biopharma Appoints a New Supervisory Board

    Nov 9, 2017 | 09:00 am

    apceth Biopharma GmbH (http://www.apceth.com/), a leading company developing the next generation of cell-based therapies, announced today the appointment of a new Supervisory Board.The Supervisory Board will be responsible for advising and supporting the company on its corporate and business strategies. The Board is composed of highly experienced members with successful track records in the pharma and biotech industry.Manfred Ruediger, Chairman,[…]

  • NeoGenomics Europe S.A. Opens its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials

    Nov 9, 2017 | 08:15 am

    NeoGenomics Inc. (https://neogenomics.com/) (NASDAQ: NEO), a leading global specialty oncology testing laboratory, opened the doors of its new Rolle, Switzerland facility on Wednesday, November 8th to bring its unique Pharma Services offering to the global research community.Rolle was chosen as NeoGenomics’ European Headquarters because of the existing talent pool, favorable business environment, and proximity to leading academic institutions in Geneva[…]

  • SOTIO Completes Enrolment of Phase III VIABLE Study in Late Stage Prostate Cancer

    Nov 6, 2017 | 10:00 am

    SOTIO (http://www.sotio.com/), a biotechnology company owned by the PPF Group, today announced the enrolment of the last patient into the VIABLE study, a global Phase III clinical trial evaluating DCVAC/PCa in combination with docetaxel in patients with metastatic castration resistant prostate cancer (mCRPC).The VIABLE study (Eudra CT: 2012-002814-38: IND: 015255) is a randomized, double blind, multicenter, parallel-group Phase III study[…]

  • Celonic Acquires Glycotope’s Bio-manufacturing Facility

    Nov 3, 2017 | 07:00 am

    Celonic AG (http://www.celonic.com/), a leading global biologics development and manufacturing services provider, and Glycotope, a clinical stage immune-oncology company, today announced the successful completion of Celonic’s acquisition of Glycotope’s (http://www.glycotope.com) bio-manufacturing facility in Heidelberg, Germany.The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with continued investment in[…]

  • RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines

    Nov 1, 2017 | 12:45 pm

    RIZAPORT® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migrainesA Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first half of 2018, if the submission is deemed complete and permits a full reviewRIZAPORT® (5mg and 10mg) was granted marketing authorization in Germany and Luxembourg under the[…]

  • Cristal Therapeutics Progresses Nanomedicine CriPec®-docetaxel to Phase 1b Development in Patients with Solid Tumours

    Nov 1, 2017 | 08:00 am

    Cristal Therapeutics (http://www.cristaltherapeutics.com/), a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a Phase 1b clinical program of its lead nanomedicine candidate CriPec®-docetaxel (https://cristaltherapeutics.com/programs/cripec-docetaxel/) in patients with solid tumours. This CriPec®-docetaxel program will evaluate the optimal frequency and dosing schedule for Phase[…]

  • BioGeneration Ventures Fund III Reaches EUR 82 Million in Final Close

    Oct 31, 2017 | 12:45 pm

    Investments from Bristol-Myers Squibb and Johnson & Johnson Innovation JJDCBioGeneration Ventures (BGV) closes its third fund, BGV III, at EUR 82 million exceeding its target to accommodate strong interest from private, institutional and strategic investorsBristol-Myers Squibb and JJDC back European early stage innovation by investing in BGV IIIPreviously announced investors include the European Investment Fund (EIF)Investment focus on entrepreneurship and[…]

  • Sartorius Stedim Biotech Wins Frost & Sullivan Award for Customer Service Leadership in Bioanalytical Contract Testing

    Oct 24, 2017 | 14:00 pm

    B3C newswire (http://www.b3cnewswire.com/home.html) -- Sartorius Stedim Biotech (https://www.sartorius.com/) (SSB), a leading international supplier for the biopharmaceutical industry, received the prestigious Frost & Sullivan’s 2017 European Customer Service Leadership Award for Bioanalytical Contract Testing Services. Presented at the Frost & Sullivan ceremony yesterday evening in London, UK, this award recognizes the unique product and service combination and enhanced customer satisfaction provided[…]

  • NeoGenomics Announces the Opening of its First International Laboratory near Geneva, Switzerland to Support Clinical Trials

    Oct 24, 2017 | 12:00 pm

    B3C newswire (http://www.b3cnewswire.com/home.html) -- NeoGenomics, Inc. (https://neogenomics.com/) (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services in the United States, announced today that it has opened its first international laboratory facility in Rolle, Switzerland, in the Canton of Vaud, just outside of Geneva as a separate subsidiary, NeoGenomics Europe, S.A.This expansion brings NeoGenomics’ unique Pharma Services menu to the[…]

  • CorFlow Completes the First Close of the Seed+ Financing Round

    Oct 24, 2017 | 06:00 am

    CorFlow Therapeutics AG (https://corflow-therapeutics.ch/) today announced that the company has completed the CHF 2.6M 1st close of its Seed+ financing round led by experienced private medical device investors who over the last decades have supported breakthrough interventional cardiology technologies. To date the company has raised more than CHF 5M in seed funding.The Seed+ proceeds will finance the 80 patients First-in-Man[…]

  • Vetter To Expand its Secondary Packaging Service Capacity to Meet Rising Demands

    Oct 19, 2017 | 13:00 pm

    B3C newswire (http://www.b3cnewswire.com/home.html) -- Vetter (https://www.vetter-pharma.com/en/home-en), a global leader in prefilled drug-delivery systems and an expert in complex packaging projects, today